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Background: The value of ferritin in the diagnosis of iron deﬁciency is limited in patients with CF since it increases in the presence of
inﬂammation. We hypothesized that the soluble transferrin receptor (sTfR) and hepcidin may provide more information than ferritin in assessing
iron status in children with CF.
Methods: We analyzed sTfR and hepcidin in relation to conventional iron status indicators in 49 children with CF.
Results: We found no differences in sTfR concentration between children with and those without ID. sTfR concentrations were within the normal
range in all children. Hepcidin concentrations were low, and concentrations below the limit of detection were observed in 25% of the clinically
stable children.
Conclusion: The sTfR is not useful to determine the iron status in this population, whereas hepcidin might serve as an early indicator of deﬁcient
iron stores in children with CF.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Children; Anemia; Ferritin; Pseudomonas aeruginosa; Hepcidin; Soluble transferrin receptor; Reticulocyte hemoglobin content1. Introduction
Iron deficiency (ID) as defined by the criteria of the World
Health Organization (WHO) (ferritin b12 μg/L or b15 μg/L) is
common in patients with cystic fibrosis (CF) [1,2]. Although the⁎ Corresponding author. Tel.: +31 70 2100000; fax: +31 70 2106959.
E-mail addresses: l.uijterschout@hagaziekenhuis.nl,
l.uijterschout@gmail.com (L. Uijterschout).
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1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Aexact mechanism is unclear, it has been suggested that ID in adult
CF patients is primarily functional due to chronic inflammation
[3]. In a recent study on iron status in children with CF we
showed that low iron stores (ferritin b12 μg/L) were common in
young children, whereas higher ferritin concentrations were
observed in older children with CF [2]. These results suggest that
unlike in adult CF patients, ID in young CF patients can be solely
attributed to an absolute ID. However, ferritin acts as an acute
phase reactant, and is therefore no reliable indicator of ID in the
presence of infection or inflammation. We suggested that thell rights reserved.
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an increased state of inflammation, rather than an improved iron
status. The results of this study might therefore underestimate the
prevalence of absolute ID in children with CF [2].
The clinical implications of ID in childrenwith CF are unclear.
In general, ID in children is associated with negative effects on
cognitive and behavioral development later in life (4). However,
the use of iron supplementation in CF patients is questionable [5]
since increased sputum iron levels are thought to contribute to the
persistence of Pseudomonas aeruginosa (PA) infections [6]. To
our knowledge, there are no data available on the effect of iron
supplementation in children with CF. Intravenous (IV) iron
supplementation in adult CF patients colonized with PA resulted
in an increase in inflammatory markers and worsening of clinical
symptoms [7], whereas no clinical deterioration was observed in
CF patients with an absolute ID [5]. The potential negative effects
of iron supplementation in CF patients likely depend upon
the underlying cause; in absolute ID patients might benefit from
iron supplementation whereas in functional ID the underlying
inflammation should be treated. The accurate assessment of iron
status is therefore highly important in the diagnosis and treatment
of ID in CF patients.
The soluble transferrin receptor (sTfR) and hepcidin might
provide more information than ferritin in assessing iron status in
patients with CF. The sTfR is expressed by iron-requiring cells
and reflects cellular iron demands and erythropoietic activity.
sTfR is less affected by inflammation than ferritin and is therefore
suggested as a biomarker that will aid in distinguishing between
absolute and functional ID [8].
Hepcidin is an iron regulatory peptide hormone, mainly pro-
duced by the liver. Hepcidin decreases intestinal iron absorption,
increases iron retention in the cells of the reticulo-endothelial
system, and thereby limits the iron availability in the circulation
for red blood cell synthesis [9]. Hepcidin is downregulated by
absolute ID, hypoxia and erythropoietic activity, and upregulated
by inflammation and infection. A recent study in adult CF
patients showed that hepcidin concentrations decrease in re-
sponse to antibiotic treatment of a pulmonary exacerbation [10].
However, no data are available on hepcidin and sTfR in children
with CF.
Since CF is characterized by continuous inflammation from an
early age [11], we hypothesized that hepcidin concentrations are
increased in children with CF, which may contribute to the
development of ID. Furthermore, we hypothesized that sTfRmay
be a more useful indicator of ID than ferritin in children with CF.
We therefore assessed sTfR and hepcidin in addition to con-
ventional iron status indicators in children with CF. Furthermore,
we analyzed the association between hepcidin and iron status
indicators, erythropoietic activity and markers of CF disease
progression such as pulmonary function, PA colonization,
pancreas insufficiency and liver function.
2. Methods
All 53 children with CF treated in our hospital were included
in the study from January 2012 to May 2013. Cystic fibrosis
transmembrane conductance regulator (CFTR) genotype wasclassified as ‘severe’ if both mutations were class I, II or III, or
‘mild’ if at least one mutation was from class IV or V, based on
previously published classifications [12,13].
A venous blood sample was taken and analyzed for sTfR,
hepcidin-25, other iron status indicators (ferritin, hemoglobin
(Hb), mean corpuscular volume (MCV), red cell distribution
width (RDW), reticulocyte hemoglobin content (Ret-Hb)),
C-reactive protein (CRP) as indicator of infection, reticulocyte
count and erythropoietin as indicators of erythropoiesis, and
albumin as indicator of liver function. Blood samples were drawn
between 8 am and 8 pm. The time of blood sampling was
categorized as before or after 12 pm, in line with previously
reported serum hepcidin concentration patterns throughout the
day [14].
Patients (≥12 years) and parents of patients (b12 years)
completed a three-day food record to assess dietary iron intake.
They received instructions by a dietician before starting the
record, and completed records were reviewed with them. We
calculated average daily intake of iron from completed records
on a personal computer using the Nutricare program (Mc
Kesson, Nieuwegein, The Netherlands). We collected data of
pulmonary function tests, results of bacterial sputum culture or
throat swab, height and body weight. Assessments were
preferably done in a stable clinical condition. However, some
children were recovering from a pulmonary exacerbation that
occurred shortly before the assessment. Assessments were
therefore classified as acute or stable, depending on the presence
or absence of an increased CRP concentration (N10 mg/L) [15]
or a pulmonary exacerbation in the preceding month. A
pulmonary exacerbation was defined as clinical deterioration
and/or decrease in pulmonary function requiring antibiotic
treatment. Children classified as acute were excluded from
further analysis. Pulmonary function test was performed and
forced expiratory volume in one second (FEV1) expressed as
percentage predicted, was chosen as representative parameters
for pulmonary function. Bacterial sputum culture or throat swab
were obtained and were sent for routine culture in the
Department of Microbiology at our institution. PA colonization
was defined as the persistent presence of PA in sputum culture
despite antibiotic treatment. Patients were defined as pancreas
insufficient when fecal elastase-1 concentration was b200 μg/g
stool. Height was measured to the nearest millimeter by using a
stadiometer. Weight was measured to the nearest 100 g by using
a digital weighting scale. Height and weight were expressed as
standard deviation scores (SDS). Body mass index (BMI)
(weight divided by height2) and BMI Z-scores were calculated.
All children (≥12 years) and parents of children (b12 years)
gave written informed consent. The study was approved by the
Medical Ethics Committee of South-West Holland.
3. Laboratory analysis
Venous blood was collected and analyzed for sTfR, hepcidin,
ferritin, Hb, MCV, RDW, Ret-Hb, CRP, reticulocytes and
albumin. Samples were centrifuged and serum was aliquoted and
frozen at −80 °C until measurement of erythropoietin and
hepcidin-25. Ferritin assays were determined using a Unicel DxI
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RDW, Ret-Hb and reticulocytes were performed using Sysmex
XE-2100 (Sysmex Corporation, Kobe, Japan) automated hema-
tology analyzers. sTfR was determined using a BN ProSpec sys-
tem (Siemens, Erlangen, Germany). Soluble transferrin receptor–
ferritin ratio (sTfR/logFer) was calculated by dividing sTfR by
log10(ferritin). Erythropoietin was determined using an Immulite
1000 (Siemens, Erlangen, Germany). Serum hepcidin-25 mea-
surements were performed by a combination of weak cation
exchange chromatography (testing lab: Hepcidinanalysis.com,
Nijmegen, The Netherlands) and time-of-flight mass spectrometry
(WCX-TOF MS) [16]. Hepcidin measurements were preceded by
one freeze–thaw cycle. An internal standard (synthetic heavy
hepcidin-25 stable isotope +40 Da; custom made Peptide
International Inc.) was used for quantification [17]. Peptide spectra
were generated on a Microflex LT matrix-enhanced laser
desorption/ionization TOF MS platform (Bruker Daltonics,
Bremen, Germany). The lower detection limit of this method
was 0.5 nM; average coefficients of variation were 2.8% (intra-
run) and 6.4% (inter-run) [17]. For hepcidin concentrations below
the limit of detection we used a value of 1/2 times the limit of
detection (e.g. 1/2 ∗ 0.5 = 0.25 nM). Hepcidin concentrations are
expressed in nanomoles per liter (nM); 1 nM serum hepcidin
equals 2.79 μg/L. ID was defined as a ferritin b12 μg/L in
children b5 years of age or ferritin b15 μg/L in children N5 years
of age, according to the criteria of the World Health Organization
[18]. Anemia was defined as Hb N 2 SD below the mean of
similarly aged children, as defined by the WHO [18]. Iron
deficiency anemia (IDA) was defined as ID in combination with
anemia. An increased sTfR and sTfR–Fer ratio were defined as a
sTfR concentration and a sTfR–logFer ratio N 2 SD above the
mean of similarly aged children as described byOoi et al. using the
same sTFR assay [19]. Pediatric reference ranges for serum
hepcidin are only available for a small group of non-anemic, iron
replete, young, Kenyan infants with a CRP b 5 mg/L, showing a
mean of 2.3 nM (P2.5 P97.5 b 0.5 − 18.1) [20].Fig. 1. Flow chart of study population. CRP: C-reactive pro4. Statistics
SPSS (version 18.0; SPSS Inc., Chicago, IL) was used for all
statistical analysis. Before analysis data were checked on
normality using histograms and Kolmogorov–Smirnov test.
Distributions of hepcidin and ferritin were positively skewed;
logarithmic transformations were applied to normalize the dis-
tributions. Data were expressed as means and standard deviations
or medians and ranges. A Student t-test for continuous variables
and a Chi-square test for dichotomous variables were used to
compare means between groups. Univariate and multivariate
linear regression analyses were used to analyze the association
between hepcidin as dependent variable and age, sex, time of
blood drawing, iron status indicators, dietary iron intake, CRP,
reticulocytes, erythropoietin, FEV1, PA colonization, pancreas
insufficiency and albumin as independent variables. A two-tailed
P value of b0.05 was considered to be statistically significant.5. Results
We included 53 children with CF (30 males, 23 females).
One child had an unknown genotype and one child had alleles
of an unknown functional class. Genotype was classified as
severe in the remaining 51 patients. None of the patients used
iron supplementation at the time of study. Iron status indicators
were available in 49 children (Fig. 1).
Increased CRP concentrations were found in 6 children (range
10–59 mg/L) and assessments were performed during an acute
episode in another 7 children (Fig. 1). Children classified as acute
(n = 13, Fig. 1) were older compared to stable children, more
frequently colonized with PA and had a poorer pulmonary
function and (Table 1). We found no differences in time of blood
sampling between acute and stable children. Mean ferritin and
hepcidin were significantly higher, and sTfR–logFer was
significantly lower in acute children compared to stable childrentein, ID: iron deficiency, IDA: iron deficiency anemia.
Table 1
Characteristics of acute and stable children with CF.
Mean (standard deviation) or number (percentage).
Acute
(n = 13)
Stable
(n = 36)
p-Value
Age (years) 12.5 (5.0) 8.9 (4.5) 0.02
Gender 8 (61.5%) 21 (58.3%) 0.84
Blood drawing b12 pm 11 (84.6%) 31 (86.1%) 0.90
BMI (Z-score) −0.59 (0.89) −0.13 (0.84) 0.11
Iron intake (mg/day) 6.3 (2.1) 8.4 (4.8) 0.50
FEV1 (% pred) 84.5 (26.5) 100.4 (14.8) 0.02
PA colonization 8 (61.5%) 11 (30.6%) 0.04
Pancreas insufficiency 13 (100.0%) 35 (97.2%) 0.56
Hb (g/L) 129.4 (11.6) 130.7 (9.7) 0.70
MCV (fL) 83.9 (3.0) 82.0 (3.8) 0.11
RDW (%) 13.2 (0.8) 13.3 (0.9) 0.87
Ret-Hb (fmol) 31.3 (1.7) 30.3 (2.4) 0.27
Ferritin (μg/L) 46.8 (27.2) 27.8 (18.8) 0.008
sTfR (mg/L) 1.3 (0.3) 1.5 (0.4) 0.09
sTfR–logFer 0.8 (0.2) 1.1 (0.4) 0.02
Reticulocytes (‰) 10.1 (3.8) 7.9 (2.6) 0.06
Hepcidin (nM) 5.2 (5.8) 1.8 (1.3) 0.001
Albumin (g/L) 37.3 (3.7) 39.6 (3.4) 0.04
Table 3
Results of linear regression analyses for serum hepcidin concentrations (nM)
adjusted for age, gender and time of blood sampling.
β 95% CI R2 p-Value
Lower limit Upper limit
Ferritin (μg/L) 0.027 0.007 0.046 45.1 0.01
Hb (g/L) 0.560 −0.136 1.256 37.9 0.11
MCV (fL) 0.032 −0.085 0.150 33.4 0.58
RDW (%) −0.294 −0.733 0.146 32.7 0.18
Ret-Hb (fmol) −0.102 −0.283 0.079 40.5 0.26
sTfR (mg/L) −0.385 −1.479 0.708 33.8 0.48
sTfR–logFer −1.081 −2.019 −0.144 42.6 0.03
Reticulocytes (‰) 0.014 −0.157 0.185 35.3 0.87
Erythropoietin (IU/L) −0.020 −0.085 0.046 33.5 0.55
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[19] was not observed in acute children.
In the remaining 36 stable children, ID and IDA were present
in 5 (13.9%) and 2 children (5.6%) respectively (Fig. 1). There
was no difference in age, gender, dietary iron intake, pulmonary
function, PA colonization or pancreas insufficiency, between
children in the ID and in the non-ID group (Table 2). No
significant difference was observed in mean sTfR concentration
between children with and those without ID. sTfR/logFer was
significantly higher in children with ID compared to those with
no ID (Table 2). However, none of the children with ID had aTable 2
Characteristics of stable CF children with ID and those with no ID.
Mean (standard deviation) or number (percentage).
ID
n = 5
No ID
n = 31
p-Value
Age (years) 11.3 (4.1) 8.6 (4.0) 0.21
Gender (male) 3 (60.0%) 18 (58.0%) 0.94
Blood drawing b12 pm 5 (100.0%) 26 (83.9%) 0.16
BMI (Z-score) −0.10 (0.89) −0.13 (0.85) 0.94
Iron intake (mg/day) 10.6 (5.9) 7.3 (4.1) 0.28
FEV1 (% pred) 102.6 (13.6) 100.0 (15.2) 0.72
PA colonization 2 (60.0%) 9 (29.0%) 0.06
Pancreas insufficiency 5 (100.0%) 30 (96.8%) 0.56
Hb (g/L) 129.8 (17.1) 130.9 (8.3) 0.82
MCV (fL) 80.2 (5.2) 82.3 (3.5) 0.26
RDW (%) 14.1 (1.0) 13.1 (0.8) 0.01
Ret-Hb (fmol) 30.1 (2.4) 30.3 (2.5) 0.87
Ferritin (μg/L) 9.8 (2.8) 30.7 (18.7) 0.02
sTfR (mg/L) 1.7 (0.3) 1.4 (0.3) 0.06
sTfR–logFer 1.8 (0.3) 1.00 (0.3) b0.001
Reticulocytes (‰) 8.0 (2.6) 7.9 (2.6) 0.96
Erythropoietin 8.8 (7.1) 10.2 (5.3) 0.69
Hepcidin (nM) 0.25 (0.0) 2.0 (1.2) 0.002
Albumin (g/L) 39.3 (2.3) 39.8 (3.8) 0.76sTfR or a sTfR/logFer above the cut-off value in similarly aged
children [19].
Hepcidin concentrations below the lower limit of detection
(b0.5 nM) were found in 9 children (25.0%), including all
children with ID (Table 2). Significantly higher hepcidin
concentrations were observed in children with no ID (Table 2).
Hepcidin concentrations were lower in blood samples obtained
before 12 pm compared to those obtained in the afternoon (1.52
(SD 1.06) and 4.43 (SD 1.36) respectively, p-value 0.001). No
association was present between hepcidin and gender, age,
dietary iron intake, erythropoietic activity or markers of CF
disease progression (data not shown). Results of a multivariate
analysis showed that hepcidin was significantly associated with
ferritin and sTfR/logFer after adjustment for age, gender and
time of blood drawing (Table 3).
6. Discussion
In this study we present for the first time concentrations of
hepcidin and sTfR in children with stable CF. ID and IDA,
as defined by the WHO criteria [18] were present in 5 (13.9%)
and 2 (5.6%) children respectively. sTfR concentrations or sTfR/
logFer N 2 SD above the mean of similarly aged children were
not observed in any of these children. The mean hepcidin
concentration was low, and concentrations below the limit of
detection were observed in 9 children (25.0%), including all
children with ID. Hepcidin was positively associated with ferritin
and sTfR/logFer, but not with erythropoietic activity or markers
of CF disease progression.
The use of sTfR and sTfR–logFer ratio did not result in the
detection of children with ID as defined by the WHO [18].
Although the sTfR/logFer was significantly higher in children
with ID compared to those with no ID, this difference was
mainly caused by lower ferritin concentrations in children with
ID. Since it has been described that sTfR starts to increase only
after severe depletion of iron stores [21,22], we suggest that ID
in our population is not severe enough to cause a significant
increase in sTfR concentration. We therefore suggest that sTfR
and sTfR/logFer are less useful in the diagnosis of ID in our
relatively healthy population of children with CF.
Hepcidin concentrations in this study were considerably lower
compared to hepcidin concentrations previously reported in 12
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severe pulmonary function impairment and increased concentra-
tions of the inflammatorymarker IL-6 [10,23], whereas children in
our study were relatively healthy with good pulmonary function in
most patients (mean FEV1 of 100.4% predicted). Even in our
acute children, mean hepcidin was lower than concentrations
observed in adult CF patients after antibiotic treatment (5.2 nM
(SD 5.8) and 8.2 nM, respectively). These data suggest that higher
hepcidin concentrations in adult CF patients represent a much
more increased state of chronic inflammation than is present in our
population of young, relatively healthy CF patients.
The lower hepcidin concentrations in our study might also be
caused by different methods of analysis that have been used.
The study in adult CF patients used a competitive enzyme-linked
immunosorbant assay (c-ELISA) [24] to measure hepcidin. The
c-ELISA gives higher hepcidin concentrations compared with the
MS-assay used in our study [16]. However, in comparison with
studies using the same MS-assay in healthy young Kenyan and
non-anemic Malawian infants, hepcidin concentrations in stable
CF children without ID in our study were similar, and only in
those with ID considerably lower [20,25,26].
Other possible explanations for the low hepcidin concentra-
tions in our study include an increased erythropoiesis due to
tissue hypoxia, and impaired hepcidin production due to liver
disease. Hypoxia-inducible factor-1 suppresses hepcidin pro-
duction via erythropoietin [27]. However, mean erythropoietin
concentration in our study was lower compared to concentra-
tions observed in another population of stable, young children
with CF [28], and similar to those observed in healthy children
[29]. Moreover, we found no association between hepcidin and
concentrations of erythropoietin or reticulocyte numbers. These
results indicate that the low hepcidin concentrations observed
in this population of stable, young CF patients, cannot be
explained by increased erythropoiesis due to tissue hypoxia.
Similarly, impaired hepcidin production due to liver disease is a
less plausible explanation since we did not find an association
between a low hepcidin and decreased albumin concentration
as an indicator of impaired hepatic function.
We found a significant association between hepcidin, ferritin
and sTfR/logFer, which suggests that the low hepcidin con-
centrations in our population reflect deficient iron stores. Since
hepcidin was associated with ferritin but not with sTfR, the
association between hepcidin and sTfR/logFer was mainly
attributed to ferritin. The positive association between hepcidin
and ferritin has been reported not only in healthy adult men and
premenopausal female blood donors [14,30,31] but also in
patients receiving hemodialysis for end-stage renal disease
[32]. This association is therefore not unique to CF and perhaps
one that is unrelated to systemic inflammation given that direct
correlations between these parameters have been described in
healthy humans.
Hepcidin concentrations below the lower limit of detection
were observed more frequently than ID, as defined by the WHO
criteria. Similar results have been reported in anemic, Gambian
children with a high prevalence of ID and concomitant infections
[33]. It has been reported that regulation of hepcidin synthesis
is more dynamic compared with ferritin, which is a specificmeasure of iron stores and varies more slowly in response to
erythropoietic iron demands [34]. Although hepcidin acts as an
acute phase reactant similar to ferritin, hepcidin declines more
rapidly after an infection or inflammatory signal has been cleared
[35]. We hypothesize that in children with ID recovering from
inflammation or an infection, hepcidin is already low to maxi-
mize iron absorption for erythropoiesis, whereas ferritin is still
above the suggested cut-off values for ID. Therefore hepcidin
might be a more sensitive indicator than ferritin to detect ID in
childrenwith a high burden of inflammation or infections, such as
CF patients. However, the clinical use of hepcidin as an indicator
of ID is hampered by the limited availability of age-specific
reference values for children.
In adults, it has been recently shown that hepcidin could
be used as an indicator of dietary iron that is needed for
erythropoiesis [33,34] and to monitor the effect of iron sup-
plementation [9] However, the beneficial effect of iron supple-
mentation in CF patients is unclear. The treatment of ID would
be desirable considering the negative effects of ID on cognitive
and psychomotor development [4] On the other hand PA
colonization was observed in 50% of children with undetect-
able hepcidin concentrations. Since PA biofilm formation
requires iron [36], iron supplementation might induce PA
colonization in these patients and is therefore questionable.
Our observation of relatively low hepcidin concentrations in
children with stable CF warrants further investigation in larger
populations. The low number of children with ID is a limitation
of our study that possibly explains the absence of a significant
difference in sTfR between children with and those without ID. A
number of 17 children in both groups would need to be studied
in order to detect a possible difference in sTfR concentration
between children with and those without ID (power of 0.8,
p-value 0.05). Another limitation of our study is that the dietary
record used in our study was not validated. Similar to all dietary
records, recall bias is a limitation in the use of the three-day food
record used in our study and this could have led to inaccurate
assessment of iron intake. Inaccurate assessment of dietary iron
intake may have contributed to the absence of an association
between a low dietary iron intake and ID in our population.
However, a 3-day food record is the most accurate method to
estimate dietary iron intake in children [37]. More insight on the
underlying mechanism of ID in CF patients and the association
between PA colonization, serum and sputum iron is warranted in
order to identify those patients who might benefit from iron
supplementation. Currently, iron supplementation should be
considered only in those CF patients with proven absolute ID
and no current infection or PA colonization.
7. Conclusion
This study shows that ID was present in 5 children (13.9%)
according to the WHO criteria. sTfR concentrations and sTfR/
logFer ratios were within the normal range in all children and
these biomarkers seem to be less useful to determine the iron
status in this population. In contrast to our expectations, hepcidin
concentrations were low and concentrations below the lower limit
of detection were observed in 9 children (25.0%). Hepcidin was
644 L. Uijterschout et al. / Journal of Cystic Fibrosis 13 (2014) 639–644associated with ferritin and sTfR/logFer, but not with markers of
erythropoietic activity or disease severity. We suggest that
hepcidin might serve as an early indicator of deficient iron stores
in children with CF. However, age-specific reference values for
hepcidin in children are urgently needed.
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